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Abstract
Tuberculosis is a transmissible disease, which is primarily caused by the bacteria Myco-
bacterium tuberculosis and by other Mycobacterium species, forming the Mycobacterium
tuberculosis complex. Until the end of the 20th Century, most cases of pulmonary tubercu-
losis were considered curable. Nevertheless, the rising of tuberculosis resistant to first-
and second-line anti-tuberculous drugs is threatening the worlds tuberculosis control
programs. Due to this fact, the World Health Organization and other public health insti-
tutions recommended applying the conventional methods, affordable by low-incoming
countries, to diagnose tuberculosis and to develop faster and more sensitive and specific
methods to identifyM. tuberculosis and determine their condition of anti-tuberculous drug
resistance or drug sensitivity. In this chapter, we mention the most used conventional and
molecular methods designed to identify M. tuberculosis and to determine their drug
sensitivity or drug resistance. We also briefly describe the fundamentals of methods and
its advantages and limitations.
Keywords: TB diagnosis, conventional and molecular methods, resistance detection
1. Introduction
Tuberculosis (TB) is a transmissible disease, which is mainly caused by the bacteria Mycobacte-
rium tuberculosis (MTB) [1] and, in a minor grade, by otherMycobacterium species, which form the
Mycobacterium tuberculosis complex (MTBC), where M. canettii, M. tuberculosis, M. africanum, M.
microti, M. pinnipedii, M. caprae, M. bovis and M. bovis Bacillus Calmette-Guérin (BCG) are included
[2, 3]. Until the last third of the 20th Century, most cases of active pulmonary tuberculosis (PTB)
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were considered curable, while the patient stringently followed an appropriate treatment. Other-
wise, eventually, patients could no longer respond to their treatment. Due to this circumstance, in
1993, the World Health Organization (WHO) recommended a global TB control strategy, called
directly observed treatment, short-course (DOTS) [4]. According to the WHO, DOTS is the most
cost-effective way to stop the spread of TB in communities with a high incidence is by curing it. This
asseveration is correct if, and only if, the MTB strain is sensitive to the first-line anti-TB drugs
(isoniazid, rifampin, ethambutol and pyrazinamide). The TB epidemiological problem arose
when drug-resistant (DR) MTB strains appeared in the world scenario. Consequently, DOTS, in
the cases of DR-TB, was no longer effective in a considerable number of TB patients, especially
when the causal agents were resistant to rifampin and isoniazid (the most effective anti-TB
drugs). This kind of DR-MTB strains is called multidrug-resistant MTB (MDR-MTB). Faced with
that situation, the WHO recommended to all government countries applying the DOTS-plus
strategy. The DOTS-plus regimen includes two or more drugs to which the isolate is susceptible,
including one drug given parenterally for 6 months ormore to patients havingMDR-TB [5]. Over
the years, the TB epidemiological situation has turned even worst. In 2006, the WHO declared a
newmodality of DR-TB as an emergency. This modality of TBwas called extensive drug-resistant
TB strains (XDR-TB), which was considered virtually untreatable with conventional drugs,
11 years ago. XDR-TB is an MDR-TB, which is also resistant to three or more second-line drugs
[6]. Nevertheless, even for these extreme cases of DR-TB, there is a hope to find a cure, consider-
ing that, lastly, new drugs are under development [6]. Therefore, it is mandatory to identify the
causal agent of TB and to determine if MTB bacteria are sensitive to first-line anti-tubercular
drugs or resistant; and, in the second case, it is also necessary to define the drug resistance profile
of each particular clinical MTB isolate.
In spite of the scientific advancesdescribed belowto identify and characterize MTB isolates, a
great challenge is facing, mainly by the developing countries, to train and hire appropriate
personnel, as well as to implement adequate diagnosis laboratories. Many countries have joined
the efforts of the WHO and other agencies to improve identification and treatment of cases of
pulmonary TB, like the Stop Tuberculosis Partnership [7]. However, it is essential to increase the
efforts of all involved, scientists, medical professionals, governments, altruist institutions and the
general population to contain and control TB. The presence of XDR-TB is an uncontrolled threat,
which could effectively become a pandemic with catastrophic consequences.
In this chapter, we describe those conventional and modern methods more often used to
diagnose, isolate characterize and determine drug resistance profiles of MTB isolates and
discuss the advantages and limitations of each of them.
2. Conventional TB diagnosis methods
2.1. Clinical diagnosis of active TB
A person is suspicious of having pulmonary tuberculosis (PTB) if shows at least 2- to 3-week
duration of cough and had or has been in contact with PTB-infectious individuals [8].
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Nevertheless, an MTB infection is usually asymptomatic in people who are well nourished and
free of complications that compromise their immune system. This form of TB is known as
latent TB infection (LTBI), which means that they do not have active TB disease, but could
develop it in the future (a process known as TB reactivation). It is estimated that one in three
people in the world has LTBI, and that, among these individuals, 510% present a risk of TB
reactivation; and most of them will develop TB within the first 5 years after their MTB
infection. Considerably, the risk of reactivation increases when predisposing factors are pre-
sent. LTBI eventually progresses to active TB, when the infected individual experiences any
condition which compromises his general health state, as HIV/AIDS or malnutrition [9]. On
the other hand, PTB is considered, if the patient presents the following signs and symptoms: a
frequent cough, usually throwing sputum (phlegm), chest pain, weakness, fever and evening
or night sweats. In advanced cases, secretions are often accompanied by blood (hemoptysis),
loss of weight, a pale skin and bright and sunken eyes [10]. The PTB diagnostic is reinforced by
a positive Mantoux test (also known as tuberculin skin test [see below]). The presence of lung
lesions (caverns), observed by a chest X-ray, denotes an advanced PTB [11, 12].
2.2. Mantoux test
The Mantoux test is performed to determine the sensitivity to tuberculin of each patient. This
test consists of inoculating on the forearm, a small amount (5.0 units of tuberculin in 0.1 mL)
intradermal (between the skin layers) of a protein extract of the mycobacteria dissolved in
glycerol. This extract is known as PPD (purified protein derivative). Determine the diameter of
the skin induration 45-72h after injection (thickened and hard skin), the halo (circle) of ery-
thema (reddening of the skin) should not be taken into account. An intradermal reaction is
considered positive when the induration diameter is 5.015.0 mm or greater. A positive test
indicates that the person was in contact with MTB, but does not necessarily indicate that
person is ill. A consideration of TB illness or not should be given if risk factors and medical
history suggest this condition. For example, a person allergic to tuberculin or one who received
the BCG vaccine against TB will give a positive reaction to tuberculin without being sick. These
people are false positives. In contrast, an individual may have a Mantoux negative reaction
and an PTB, if he also has AIDS (having his immune system compromised). Thus, this
individual is anergic and a false negative [13].
2.3. Chest X-ray
Chest radiographs should be used to rule out the possibility of PTB in a person who has a
positive reaction to a tuberculin skin test and no symptoms of the disease. An anteroposterior
chest X-ray is one of the most important tests to be performed in a patient having TB or
suspected TB. Chest X-ray findings include parenchymal infiltrates, hilar adenopathy, cavita-
tion, nodules and pleural effusion [14]. Infiltrates or consolidations and cavities are often seen
at the lung upper lobes, with or without mediastinal or hilar lymphadenopathy. However,
lesions may appear anywhere in the lungs. In HIV/AIDS suffers or other immunosuppressed
persons, any abnormality may indicate TB. In contrast, the chest X-ray may even appear
entirely normal. On the other hand, longstanding healed TB lesions are usually presented as
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pulmonary nodules in their hilar area or upper lobes, with or without fibrotic scars, volume
loss and bronchiectasis (enlargement of parts of the airways within the lung). Furthermore,
pleural scarring may be present. Nodules and fibrotic scars may contain slowly multiplying
tubercle bacilli with the potential for future progression to active TB. Persons showing these
lesions, if they have a positive tuberculin skin test reaction, should be considered high-priority
candidates for the treatment of latent infection, regardless of age. Conversely, calcified nodular
lesions (calcified granuloma) represent a very low risk for future progression to active TB [15].
2.4. Classical laboratory methods to identify PTB
Classical laboratory methods to identify MTB are used worldwide due to these are very useful
and reliable.
TB-diagnostic methods are the detection of mycobacteria, by acid-fast bacilli (AFB) staining and
fluorescence microscopy and isolation and cultivation of mycobacteria, allow establishing a most
specific diagnostic of PTB than only above clinical diagnostic methods. Both identifying, isolating
and characterizing MTB in a patient sputum along with a PTB clinical picture are necessary
because to all signs and symptoms of PTB, described above,may be confusedwith other diseases,
such as coccidiomycosis [16]. In other words, it is essential, in first instance, a clinical diagnostic of
PTB and confirm or discard it by conventional laboratory procedures [11, 12].
3. Detection of AFB
3.1. Ziehl-Neelsen staining (ZN)
Mycobacteria are not well stained by Grams method. Therefore, alternative methods were
developed long time ago. The most commonly used technique to identify AFB is ZN. Notwith-
standing, this method is not 100% specific or sensitive for MTB, since some bacteria species,
like those of the Nocardia genus, are also AFB [17]. In addition, there are more than 120 species
of mycobacteria, which are not causal agents of PTB and that also are AFB. On the contrary,
some mycobacteria produce atypical pulmonary symptoms that are not MTB [18].
The ZN staining consists of dying, discoloring, counterstain and observing. The culture in
suspension, or a liquid biological sample, is deposited onto a slide and dried and fixed with a
flux of heat air. The slide is submerged into a phenol-carbol fuchsin solution; then, this smear is
heated to enable the dye that penetrates the waxy mycobacterial cell wall and bind mycolic
acids. Once the preparation was dyed, this is rinsed with tap water, and an acid decolorizing
solution (1% solution of hydrochloric acid in isopropyl alcohol or methanol) is applied to
remove the red dye from any non-AFB cell or material. Only AFBs (such as mycobacteria) will
retain the phenol-carbol fuchsin dye, because of the protection provided by a waxy lipid layer,
characteristic of AFB. After discoloration of the sputum smear, counterstaining is performed
with malachite green or methylene blue, which will stain non-AFB material that was not able
to retain the first dye. After that, a contrast between the red AFB, of the non-AFB material
green or blue color will be observed with a microscope. The above procedure may vary due to
structural differences between mycobacteria genera. For instance, M. ulcerans is strongly AFB,
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whereas others, like M. leprae, are weakly AFB. M. ulcerans is decolorized with 3% ethanol,
whereas it is needed 0.51% sulfuric acid to decolorize M. leprae [19]; in addition, the staining
and discoloration times can also change from one mycobacterium genera to another.
The ZN is considered as the gold standard. This technique requires highly trained personnel in
AFB staining and detection. According to the WHO [20], the AFB detection time and training
of specialized personnel need to be improved, and so make TB diagnoses and start treatments
for patients in a more opportune manner [20].
3.2. Fluorescence microscopy
An alternative for ZN staining is fluorescence microscopy (FM), which is currently used in
many laboratories with available equipment. FM is faster than ZN, because FM allows visual-
ize MTB bacilli in an easier manner than ZN. An FM study lasts 1.0 min and ZN requires
4.0 min. In addition, FM has been shown to be at least 10% more sensitive than classical light
microscopy [21]. In high-volume laboratories, rapid laboratory turnaround times can prove to
be crucial in the diagnosis of presumptive mycobacterial disease. In such settings, test charac-
teristics such as staining time and background fluorescence contribute to overall laboratory
efficiency in reporting results [22]. Also, FM is a semi-automated method and ZN must be
carried out manually and to observe AFB directly under the microscope, by an experimented
operator. On the other hand, ZN method is more affordable for low-resource institutions than
FM, since fluorescence microscopes are noticeably more expensive than light-field micro-
scopes, which are used to perform a sputum inspection.
Auramine and rhodamine are the main stains used in FM to detect mycobacteria in biological
samples. These dyes are non-specific fluorochromes that bind mycolic acids of the mycobacte-
rial wall. Once the dye has penetrated into the MTB wall, the mycolic acid-dye complex resists
discoloration by alcohol-acid solutions. Counterstain helps to prevent fluorescence other than
AFB, thus making the test more specific by reducing the possibility of artifacts. Counterstain is
done with potassium permanganate. Once the staining is finished, AFBs are observed under
an epifluorescence microscope. Under the UV light, AFBs gleam in yellow or bright orange
over a dark background. The AFB-screening examination of smears is performed with a
fluorescent microscope equipped with a 20X or 40X objective and a 100X oil immersion
objective to observe the morphology of fluorescing organisms [23].
Nowadays, there are available new systems for identifying mycobacteria in clinical samples,
which is based on light-emitting diodes (LEDs). This LED system costs considerably less than
the original system and deserves to be evaluated in developing countries [24]. One of these
methods describes an adaptation of a standard fluorescent microscope for illumination using a
Royal Blue Luxeon™ LED and demonstrates that this form of lighting is suitable for detection
of auramine O-stained Mycobacterium spp. The authors claim that their method is of low cost,
low power consumption, safety and that the reliability of LEDs makes them an attractive
alternative for mercury vapor lamps [25].
In conclusion, in spite of the usefulness of AFB stain, using the ZN staining or FM, without a
mycobacteria culture, AFB visualization has a poor negative predictive value. An AFB culture
should be performed along with an AFB stain; this has a much higher negative predictive value.
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4. Isolation and culture of MTB
4.1. Conventional procedure
All following procedures mandatorily are carried out in laboratories of level III microbiological
contention and must be performed by trained personnel. A TB diagnostic must include an
identification of MTB in appropriate biological samples. This is achieved by isolating the infec-
tious agents and observing their colonies, developed in a solid culture medium (usually
Lowenstein-Jensens). Typically, PTB forms white, opaque, cauliflower-shaped colonies. Using a
few of these colonies, the biological and biochemical characteristics of the isolates must be
determined to identify MTB [26]. It must be kept in mind that a definitive TB diagnostic must be
integrated by the correspondent clinical signs and symptoms and the bacteriological findings [27].
A standard laboratory procedure to identify MTB consists of decontaminate and liquefy
freshly obtained sputum samples. One of the most used methods to liquefy and decontaminate
sputum is Petroffs method, which has been modified several times [28]. One of the most
important characteristics of method consists of the destruction, by sodium hydroxide, of many
of the rapidly growing micro-organisms, which are contaminating to biological samples. After
this decontamination, the viable bacteria are concentrated by centrifugation. The sediment is
inoculated in a culture medium and incubated at 37C in a 5% CO2 atmosphere until typical
MTB colonies are observed. The most used method to isolate MTB from sputum or other body
fluids, like urine or cerebrospinal fluid, is the Lowenstein-Jensen solid medium, which usual
composition is malachite green, glycerol, asparagine, hens eggs and a salt solution (composed
by potassium dihydro phosphate, magnesium sulfate and sodium citrate). The medium is
aliquoted, put into glass screw-tapped bottom flat tubes and coagulated in an oven by heat.
The sedimented bacteria are inoculated on the surface of a Lowenstein-Jensen medium slant.
MTB is characterized by a slow growth, being its doubling time 1020 h. It is required to
incubate the sputum preparations for 58 weeks before typical colonies appear. Usually, the
slow growth of mycobacteria in vitro is an obstacle to start an adequate treatment for TB
opportunely. Other essential bacteriological characteristics of MTB are as follows: unlike other
mycobacteria, MTB colonies are white (they do not produce pigments in the presence or
absence of light) [29]. MTB is niacin- and catalase-positive and reduces nitrates to nitrites [30].
AFB detection by microscopy, plus culture, isolation of mycobacteria and their laboratory
biochemical characterization are the gold standard for TB diagnosis. Even though the pro-
cesses above have a low sensitivity (between 60 and 80%) [30], the generalized use of the theme
is vital for preventing TB spreading worldwide, with an emphasis in DR-TB and XDR-TB [2].
4.2. Automated procedure
At a date, a totally automated system is available. This system is the BD BACTEC™ MGIT™
Automated Mycobacterial Detection System 960. MGITmeans Mycobacteria Growth Indicator
Tubes (MGIT). The BD BACTEC™ MGIT™ system offers several advantages over other tests
and systems, among which can be emphasized an easy operation, an automated and a contin-
uous quality checks, saving hours of work of the personnel, as well as of the equipment. By
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showing positivity as it happens, time is optimized for patient care. It also uses barcode
technology to facilitate data entry and processing, and patient and sample tracking.
The fundamentals of BD BACTEC™MGIT™ system is as follows: at bottom of each MGITunit
is placed an oxygen-quenched fluorochrome (tris 4,7-diphenyl-1, 10-phenonthroline ruthenium
chloride pentahydrate) embedded in silicone. As mycobacteria grow into the culture tube: the
free oxygen is utilized and replaced by carbon dioxide. Because of depletion of free oxygen, into
the culture tube, the fluorochrome is no longer inhibited, resulting in fluorescence within the
MGIT tube: under a source of UV light a fluorochrome is stimulated and emits visible light. The
fluorescence is quantified by the instrument, as the intensity of fluorescence is directly propor-
tional to the extent of oxygen depletion and, therefore, to the concentration of viable
mycobacteria.
Procedure. Each MGIT unit contains 7.0 ml sterile modified Middlebrook 7H9 broth base,
which must be added with MGIT PANTAan antibiotic mixture designed for suppress
contaminationOADC (oleic acid, albumin, dextrose and catalase) or, preferably, MGIT 960
growth supplement. According to the manufacturer, MGIT growth supplement is essential for
growth of mycobacteria belonging to MTBC. MGIT tubes are incubated, inside the instrument,
and monitored for increasing fluorescence every 60 min. Under the above conditions, a typical
MTB culture reaches a concentration of mycobacteria equivalent to 105106 colony forming
units (CFU) per mL. On the other hand, when a preparation remains non-fluorescent after 6
weeks (42 days), it is considered as negative. The presence of contaminating bacteria can be
detected, because these microorganisms generally produce a heavy turbidity [31].
5. Determination of MTB drug resistance
5.1. Conventional methods
Once MTB isolates are identified, it is necessary to determine their drug resistance profile.
Conventional drug-resistant tests (DRTs) are first used to evaluate resistance to streptomycin,
isoniazid, rifampin, ethambutol and pyrazinamide. This information is crucial for the treating
physician knows if DOTS will be effective to cure a patient having TB. Nevertheless, if a
particular isolate shows resistance to rifampin, isoniazid or both drugs, the resistance profile to
second-line drugs [injectable aminoglycosides (amikacin or kanamycin), capreomycin and
fluoroquinolones] must be determined [32]. This information will permit that the physician
decides if the patient should be treated with a combination of first- and second-line drugs,
following the current recommendations of the WHO for MD-TB. Three of the most used DRTs
are the classical agar proportion method, the BACTEC 960 fluorometric method and microplate
Alamar blue assay (MABA).
5.2. Agar proportion method
The method of proportion using Middlebrook 7H10 agar has been considered the gold
standard method for several decades. This method allows separate the resistant bacilli from
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the susceptible bacilli and establishes their proportions in the culture (% of resistant bacilli and
% of sensible bacilli to a particular drug). This information is obtained by culturing the isolated
strain in duplicate. One slant or plate has only Middlebrook 7H10 agar, and the duplicate is
cultured with the same medium, added with the anti-tuberculous drug to be evaluated. Then,
the percentage of colony forming units (CFU) present in the treated culture is calculated with
respect to the total number of CFU found in the untreated culture [33].
5.3. Fluorometric method: BACTEC 960 system
The BACTEC MGIT 960 SIRE (streptomycin, isoniazid, rifampin and ethambutol) and PZA
(pyrazinamide) susceptibility test for MTB are used extensively in the world to identify the
presence of mycobacteria in biological samples and to determine the sensitivity to first-line
drugs [34]. The drug susceptibility test, using this system, is based on the same principle than
the aforementioned BACTEC 960 system for mycobacteria detection, and the same instrument
is used, but following the particularities that request this drug-sensibility system. The proce-
dure is as follows: twoMGITunits are needed to perform the mycobacteria DRTs for each first-
line anti-MTB drug. Each tube is inoculated with the test mycobacteria culture. One MGIT unit
is added with a known concentration of one of the test anti-MTB drugs, and the other one is a
non-treated growth control, which is inoculated and incubated under the same conditions than
the test culture. Mycobacteria growth is monitored by the BACTEC 960 instrument, which
automatically interprets if a particular culture is susceptible or resistant to the drug of interest.
In other words, when the control culture reaches a mycobacteria concentration equivalent to
105106 CFU, in about 78 days, the growth in the test tube is compared with the control. If the
test drug is active against the isolated mycobacteria, its fluorescence will be significantly lower
than controls.
5.4. Microplate Alamar Blue Assay (MABA)
MABA is a micromethod, which takes advantage of the dichromatism of resazurin: when
the medium is reduced, resazurin changes irreversibly from blue to an intense pink and also
intensely fluoresces under UV light. In addition, resazurin is soluble in water. These
remarkable properties made possible that Alamar blueTM or resazurin has been widely
used to determine cell viability and growth in MTB and many other cells and microorgan-
isms [35]. MABA has been specifically applied to determine drug resistance of MTB [36] in
synthetic, semisynthetic [37] and natural products [38]. MABA is also used to determine the
minimal inhibitory concentrations (MIC) of isoniazid, rifampin, streptomycin and etham-
butol in MTB. In general, the procedure followed with MABA consists of using bacterial
suspensions having approximately 6  106 (CFU)/mL. The product to be evaluated for its
anti-MTB activity is previously sterilizedby filtration or dissolved in 100% dimethyl
sulfoxide (DMSO)and then diluted in fresh Middlebrook 7H9 broth supplemented with
an oleic acid dextrose catalase supplement (OADC). Then, 200 μL of this mycobacterial
suspension are put into the first well of 96-well microplates. From this well, a twofold
diluted series is formed, using the remaining wells, placed in the same lane than the first.
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The MIC of the evaluated product is equivalent to its concentration being in the first pink-
colored well [38].
5.5. Tools for molecular diagnosis and drug resistance determination
During the last decades, the number of tests to identify MTB has been growing rapidly. Today,
the molecular diagnostic tools are faster, more sensitive and more specific than the conven-
tional tools. Nevertheless, the conventional microbiological methods remain being the gold
standards. Furthermore, the isolation, culture, identification of MTB and determination of first-
and second-line anti-TB drug profile have not been replaced, with advantage, by any molecu-
lar tool. In other words, currently, molecular diagnosis tools are only complimentary for
traditional diagnosis methods.
5.6. Molecular diagnosis tools
Currently, many molecular tools are available. In general, these methods analyze MTB-DNA
or -RNA by polymerase chain reaction (PCR)-amplification, with very few exceptions. There
are three basic molecular procedures for amplifying MTB nucleic acids: PCR final point, RT-
PCR and quantitative or real-time PCR (qPCR). In addition, multiple variants have been
described for the above nucleic acid amplification methods (see below). In general, the above
methods detect polymorphisms, mutations or deletions to discriminate between MTB and
other bacteria species and different MTB clusters. In addition, molecular methods offer the
possibility of rapidly and accurately identifying MTB, genotyping and determining resistance
to rifampin or rifampin and isoniazid [30, 39, 40].
5.7. Main genetic markers to identify MTB
The genetic markers currently used to identify and classify MTB are as follows: the IS6110
insertion element, the gene encoding the 65-kDa heat shock protein, named hsp65, a polymor-
phic guanine-cytosine-rich sequence (PGRS-RFLP), mycobacterial interspersed repetitive
units-variable number tandem repeat (MIRU-VNTR), direct repeats (DRs) or clustered regu-
larly interspersed short palindromic repeats (CRISPR), single nucleotide polymorphisms
(SNPs) and large sequence polymorphisms (LSPs) [41]. Nevertheless, not all the above markers
are used in identifying MTB with clinical purposes, but in epidemiological and basic studies.
Thus, in the following paragraphs, we discuss only the markers and methods useful to identify
MTB with TB-diagnosis purposes, although some of them are also using to perform epidemi-
ological studies.
IS6110 considered as an ideal target to identify MTB and classify clinical isolates in clusters,
according to their random fragment length polymorphism (RFLP [see below]). IS6110 is ran-
domly distributed throughout the MTB genome and its number of copies ranges from 0 to 26
[42]. A limitation of RFLP-based detection of IS6110 is the inability of this method to discrim-
inate strains with less than six copies of IS6110. This situation is especially important in India.
Narayanan et al. in 2002 reported that 41% of clinical isolates contained a single copy of IS6110
[43]. In addition, Sankar et al. specifically pointed IS6110 as a molecular target that is not
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sensitive enough to encompass all TB cases, especially PTB. In fact, it is well known that some
MTB strains lack the element IS6110 [44]. However, a group of investigators reported up to
94.1%MTB in clinical isolates using IS6110 as the molecular target and nested PCRsee below
as the method of choice. Until relatively recently, IS6110 was considered exclusive to the
MTBC. However, Coros et al. [45] reported thatM. smegmatis also has the IS6110 element. This
latter finding could negatively affect the specificity of IS6110.
Gene hsp65. The second most widely used molecular target is hsp65. This gene encodes for a
heat shock protein of 65 kda, and the MTB genome contains a single copy of that gene.
Variations in the primary sequence of hsp65 serve to identify species of rapidly and slowly
growing mycobacteria [46]. The limitation of this target for the molecular diagnosis of TB is
precise that the MTB genome has a single copy of the hsp65 gene.
Direct repeats. The direct repeat (DR) region in MTBC strains (do not confuse DR region) with
drug resistance, see above]) is a fragment of DNA located in a hot spot for the integration of IS
elements. This region is composed of multiple repeat sequences of direct variants (DVRS).
Each DR replicate [47] is composed of 36 bp repetitive sequences separated by a non-repetitive
sequence of 3541 bp in size called spacers [48]. Generally, each spacer is found only once in
the DR region. During the MTB evolution, some spacers could be deleted from the MTB-
genome, due to a high mutation rate in the DR region [49]. Genome DR region of MTBC
strains is extensively used for genotyping mycobacteria, due to DR spoligotyping-based pat-
terns allow distinguishing MTB from M. bovis and other members of the MTBC [47].
6. Methods to identify MTB in biological samples
6.1. Method to determine RFLP
This method is an exception for others based on nucleic acid amplification. Therefore, it is
necessary purifying a considerably greater quantity of DNA from MTB isolates than the DNA
quantity needed for those methods based on nucleic acids amplification. RFLP consists in
isolating, propagating MTB, purifying the DNA, cutting up the DNA with a specific restriction
enzyme, separating the fragments by gel-electrophoresis, hybridizing the DNA fragments with
an IS6110 labeled probe and visualizing the RFLP pattern and analyzing it [50].
6.2. Methods to identify MTB by amplifying its genomic DNA
6.2.1. Polymerase chain reaction (PCR)
PCR provides a very useful tool for diagnosing TB. The endpoint PCR has two clinical applica-
tions: the identification of MTB and the determination of drug resistance of the clinical isolates.
6.2.2. End-point PCR
A typical analysis of end-point PCR consists in a separation of the PCR product by gel-
electrophoresis and its visualization and certification of the expected PCR product. Originally,
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end-point PCR was described by Kary Banks Mullis, who received the Nobel Prize in chemis-
try in 1993, for his invention of this procedure. The process, which Mullis conceptualized in
1983, is hailed as one of the monumental scientific techniques of the twentieth century [51].
PCR allows obtaining millions of DNA or RNA ―see below―sequences from few original
copies of the sequences of interest, called amplicons [2]. The success of molecular detection of
MTB depends on the quality of the biological samples, the methods of extraction of the nucleic
acids and the amplification and detection techniques. In addition, it is of fundamental impor-
tance to select the appropriate amplicons and to design and synthesize the complementary
oligonucleotides (primers) to generate genuine DNA copies of the amplicons [52].
MTB identification by PCR can be done starting from sputum samples, MTB isolates or MTB
laboratory strains (as H37Rv). In general, the PCR procedure, starting from sputum, is as
follows: the sputum sample is decontaminated and concentrated usually using Petroff’s method
and centrifugation (see above). Mycobacteria are washed with a saline pH buffer and lysed by
incubating them with a solution of lysozyme, proteinase K and sodium dodecyl sulfate (SDS).
The DNA is extracted with chloroform-cetyl trimethyl ammonium bromide (chloroform-CTAB)
and precipitated with isopropanol. The amplification of specific regions of DNA needs a very
pure and non-degraded DNA, a heat-resistant DNA polymerase (usually Taq polymerase, which
is obtained from the thermophile bacteria Thermus aquaticus), a mixture of the four deoxyribonu-
cleoside triphosphates [deoxyadenosine triphosphate (dATP), deoxyguanosine triphosphate
(dGTP), deoxycytidine triphosphate (dCTP) and deoxythymidine triphosphate (dTTP)], a pH
buffer solution, salts of Mg2+ or Mn2+ and K+ and a pair of DNA primers, which sequences are
complementary to the 30 ends of the two DNA strands, embracing the region to be amplified.
Typically, PCR consists of a series of 20–40 cycles. Each cycle consist of three steps: (1) denatur-
ation of DNA at >90C (separation of the two strands of DNA), (2) annealing (hybridization of
primers with each DNA strand) and (3) extension (synthesis of the two new DNA strands) [53].
The analysis of DNA fragments produced by PCR consists of separate them according to their
size (number of base-pairs [bp]). DNA band separation is achieved by applying an electropho-
resis run in gels of agarose. After the electrophoresis is complete, DNA appears ordered in the
gel as bands, from the heaviest (top) to the lightest (bottom). DNA bands in the gel must be
stained to make them visible. DNA may be visualized using ethidium bromide, which, when
intercalated into DNA, fluoresces under ultraviolet light. This stain must be managed care-
fully, using adequate protective equipment, because ethidium bromide is carcinogenic. A good
alternative is using fluorescent-specific DNA stains, like GelStar® and SYBR® Green. Both
strains are very sensitive and offer the advantage, over ethidium bromide, of being non-
carcinogenic. In addition, it is not necessary washing the gels after staining for increasing the
specificity of analyses. Therefore, both stains are excellent for detecting nucleic acids in agarose
gels. GelStar is used to detect both single-stranded and double-stranded DNA and RNA,
whereas SYBR Green is preferred for visualizing bands of double-stranded DNA in gel elec-
trophoresis [54]. Then, the PCR product is sized, with the aid of a DNA molecular weight
ladder, which must be placed in the same gel of experimental DNA, before running the
electrophoresis. Usually, the first lane at left of the gel is chosen to put the molecular weight
ladder. This DNA-size ladder is formed by a set of double-stranded DNA fragments having
known and different sizes. The size of PCR products is estimated by interpolation or simply
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comparing the position of the DNA marker, having a size equivalent to the size expected for
the PCR product of interest. The identification on the gel of the amplified product with the
expected molecular weight indicates the presence of an MTBC member in the sample studied
[55, 56].
6.3. Variations of PCR-final point of DNA
The main variations of the basic point final PCR are nested PCR, multiplex PCR, spoligotyping
[57, 58] and RFLP-PCR. These variants were designed to improve the sensitivity and specificity
of basic RFLP and PCR.
6.3.1. Nested PCR
Nested PCR is widely used, because this method significantly improves the sensitivity and
specificity of basic PCR. The nested PCR consists of using two sets of primers, both directed
against the same target DNA sequence, which may be a gene or some other region character-
istic of a mycobacterial species [59]. The first set of primers is designed to hybridize to the most
distal regions of the target sequence, the first amplification run is made and the resulting
amplicons are used, in turn, to amplify a slightly inner region of the used original target
sequence. Once performed the first series of PCR cycles, the PCR is used to carry out the
second amplification procedure. Prasad et al. designed a nested PCR-based assay using the
hupB gene of MTB (Rv2986c) and M. bovis (Mb3010c) as a method to differentiate these two
closely related species [60]. Our research group developed a method for the diagnosis of TB
based on nested PCR that targets the gene coding for the β-subunit of MTB RNA polymerase.
This method is noticeably more specific and sensitive than all that have been published to date
or have been approved by the FDA. Most current methods require cultivating mycobacteria
for a few days and do not work with certain types of samples. In contrast, our method can
work well with the genome of a single bacterium and samples of sputum [61] or cerebrospinal
fluid [62], without the need to culture the biological samples. Currently, the patent is in a
process.
6.3.2. Multiplex PCR
Multiplex PCR refers to the use of PCR to amplify, simultaneously, several different DNA
sequences. That is to say, multiplex PCR allows performing many separate PCR reactions, all
together, carrying out only one procedure. Otherwise, amplification by PCR of several DNA
sequences would require several runs, as well as more reagents and longer time to perform
them. On the other hand, if additional information is required from a particular DNA
sequence, this may be gained by accomplishing a single, conventional PCR test.
PCR multiplex has enormous value in infectious disease that can be caused by a variety of
microorganisms, for instance, meningitis. Meningitis can be caused by MTB [63], several other
bacterial species (Streptococcus pneumoniae, Haemophilus influenzae type b,N. meningitidis, group
b Streptococcus and Listeria monocytogenes) [64] and fungi [65]. Meningitis is a medical emer-
gency, and immediate steps must be taken to establish the specific cause and initiate effective
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therapy [66]. PCR multiplex is a rapid, sensitive and specific diagnostic test for acute bacterial
meningitis. PCR is particularly useful for analyzing cerebrospinal fluid of patients who have
been treated with antibiotics before lumbar puncture [64]. Furthermore, in 2002, Shah et al. [67]
reported a multiplex PCR-based assay performing a rapid and specific differentiation of M.
bovis and MTB. This procedure can be beneficial for medical and veterinary microbiological
laboratories. The designed multiplex PCR to identify MTB or M. bovis is based on the differen-
tial amplification of pncA gene. This test is highly specific and sensitive. Only 20 pg of pure
mycobacteria DNA are needed, and none PCR amplification product has been obtained from
any atypical mycobacterial isolate.
There is a series of requirements to be met to perform a good multiplex PCR analysis. These are
as follows: (1) Accomplish the standard requirements for primer design. (2) Design one pair of
primers for each expected amplicon. (3) Apply suitable temperatures, allowing DNA polymer-
ase works accurately in every multiplex PCR cycle. (4) The primer design must be optimized;
so that, all primer pairs work properly, at the same time and in a single reaction. (5) Apply
similar alignment temperatures for all primers. (6) Choose the size of those DNA regions to be
amplified so that be possible obtaining amplicons having clearly different sizes among them.
Allowing, in this way, to distinguish the bands between them in the electrophoresis gel, (7) in
case of needing to differentiate amplicons having the same size, the primers must be labeled
with fluorescent dyes having distinctive colors. For certain multiplex analyses, commercial
multiplexing kits are available. It has been informed that multiplex PCR has a sensitivity and
specificity of 95% [68].
6.3.3. Random fragment length polymorphism (RFLP)-PCR
RFLP-PCR is a fast and reliable method for identifying non-TB mycobacteria [69]. This method
is based on amplifying fragments of diverse genes; for instance, hsp65, the gene for histone-
like protein hupB and pncA. Gene hsp65 are present in all species of mycobacteria. The
selected target of hsp65 gene is a 439 bp fragment. Using hsp65 can be distinguished between
MTB, M. avium and M. intracellulare, but not between MTB and M. bovis [70]. Gene hupB
encodes for an histone-like protein. RFLP-PCR of hupB allows differentiation of MTB and M.
bovis. The amplicons generated have 645 bp and 618 bp, respectively. pncA PCR assays were
found specific in detecting MTB and M. bovis, as well as the M. avium complex in human
sputum [71].
6.3.4. Real-time PCR
Real-time PCR, also known as quantitative PCR (qPCR), offers several advantages over end-
point PCR, which are as follows: (1) as its name indicates, it is quantitative; (2) reduces the risk
of cross-contamination because it minimizes the need to manipulate samples after performing
PCR; (3) the manual processing time is reduced; (4) the run preparation times are also reduced
and (5) offers high sensitivity and specificity [72]. Since the last decade, qPCR for the detection
of MTB target genes in clinical specimens has contributed to improved diagnosis and epidemi-
ological studies of TB. This is because qPCR offers the advantage of combining amplification
and detection of molecular targets in a single step; and there is no need to use nested PCR [73].
Conventional and Molecular Diagnosis of Drug-Sensitive and Drug-Resistant Pulmonary Tuberculosis
http://dx.doi.org/10.5772/intechopen.75004
83
Therefore, qPCR is rendering obsolete those techniques based on end-point PCR, which are
much less sensitive. The qPCR technique involves the use of fluorescent chromophores
(fluorophores) covalently attached to the primers. The fluorophore is placed at the 50end of
the primer (probe) and at the 30 end or internally, a fluorescence quencher is inserted cova-
lently. During the PCR extension phase, the exonuclease activity of the Taq polymerase cuts the
initiator in the 50-30direction, and the fluorophore and quencher are separated, which results
in a detectable fluorescence that is proportional with the number of accumulated amplicons. A
spectrofluorometer integrated with the thermocycler reads the emerging fluorescence. The
PCR occurs in a dynamic way, and the results are read continuously. A computer integrated
with the equipment, with the help of specialized software that accumulates and analyzes the
data, generates a DNA amplification curve under study. The computer program allows mon-
itoring the amplification curve on a screen. Usually, an analysis of qPCR is carried out in 1.5 h.
The analysis described above can be performed with different platforms. SYBR green (cyanine
colorant) is widely used for qPCR because it is very sensitive and high cost/benefit in uniplex
formats. Besides of SYBR green, a number of options are available, such as TaqMan probes,
molecular beacons, scorpion primers, fluorescence resonance energy transfer probes (FRETS)
and primer-probe energy transfer. There are also different fluorescent chromophores, e.g.
6-carboxyfluorescein-aminohexyl amidite (6-FAM), carboxy-X-rhodamine (ROX) and cyanine
(Cy5) as reporters at the 50end and a quencher at the 30 end. Considering the advantages and
disadvantages of IS6110 and of hsp65 discussed above, some authors have proposed using
them in a multiplex qPCR format, which would presumably offer a more specific and inclusive
diagnosis [2].
6.3.5. Real-time (RT) PCR
RT-PCR allows to amplify specific regions of the MTB genome or to obtain DNA starting
from RNA by using a reverse transcriptase. This form of PCR is called RT-PCR (reverse
transcriptase-PCR). The nested RT-PCR is a variation of the nested-PCR. Nested RT-PCR
offers the same advantages than nested PCR, discussed above; with the difference that
nested RT-PCR allows obtaining a cDNA strand, using the original mRNA sequence as
template. A reverse transcriptase is used instead of a DNA polymerase to synthesize the
cDNA. Then, like in nested PCR, the first set of primers is designed to hybridize to the most
distal regions of the target sequence, the first amplification run is made and the resulting
amplicons are used, in turn, to amplify a slightly inner region of the used original target
sequence [59].
6.3.6. Spoligotyping
Besides of PCR multiplex, spoligotyping offers the possibility of distinguishing between M.
bovis and MTB. Forty-three types of mycobacterial spacers are known. Of these, 37 are typical
of MTB and other 6 of M. bovis BCG. An edition of the international spoligotyping database
namely SpolDB4/SITVIT was introduced containing 1939 different spoligotypes (ST) identi-
fied. Furthermore, spoligotyping allows grouping MTB isolates according to the presence or
absence of intermediate regions of the DR locus (direct repeats) in each MTB isolate, forming
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specific patterns. The DR locus is a member of the CRISPR (clustered regularly interspaced
short palindromic repeats) family of the MTBC.
Spoligotyping is used to analyze genetic diversity of DR locus. It is useful for clinical, molecu-
lar epidemiology, evolution and population genetics laboratories [74]. This method is relatively
easy to use, robust and allows numerical analysis. Spoligotyping was designed to detect
biotinylated, amplified products from MTB and M. bovis from the DR locus. This method is
based on reverse hybridization to the spacer sequences (43 synthetic oligonucleotides), which
are covalently attached as lines to a nylon membrane. The hybridization is performed by
turning 90 the amplicon template concerning the immobilized synthetic oligonucleotides. To
immobilize the perpendicular samples, an acrylic device is used. So that, each homology will
give rise to a tiny square of hybridization. Non-hybridizing products are eliminated with
successive washes and will leave a blank space where the correspondent synthetic oligonucle-
otide is placed. On the other hand, those hybridized products will be detected using the
streptavidin-peroxidase system, which binds to the biotin present in the amplified products.
Results are visualized by incubating the hybridization template with luminol, in such a way
that peroxidase catalyzes the oxidation of the reagent, resulting in light emission, which is
developed by exposing the membrane to an X-ray film. The patterns obtained to reveal
absence or presence of the spacers is read as a binary code, which can be easily interpreted
and computerized. A commercial kit for MTB spoligotyping is available. In addition, a
spoligotyping databases from MTB and M. bovis isolates from worldwide are available online.
6.4. Methods to determine MTB-drug resistance
6.4.1. End-point PCR to determine MTB-MDR
Most PCR-based tests described above were designed exclusively to detect the presence of
MTB in biological samples. Fortunately, there are other PCR-based tests designed to identify
MTB in biological samples and to know whether these microorganisms are resistant to rifam-
picin or rifampicin and isoniazid. The most important tests are described below.
The methods for detecting resistance to anti-TB drugs are based on the detection of mutations
in the genes that are associated with that resistance condition and this is achieved by the
application of sequencing or hybridization techniques. Recent advances in the rapid and direct
detection of mycobacteria, with an emphasis on MTB, are based on the analysis of 16S rRNA
gene sequence or oligonucleotide hybridization (oligohybridization), typing of strains and
detection of patterns of drug susceptibility. Semi-automated systems for culture have greatly
increased sensitivity and reduced the time required to perform the detection and identification
of mycobacteria in clinical specimens. However, further research is still needed to assess the
impact and cost/benefit of new diagnosis methods. In addition, well-designed clinical trials are
still required to evaluate new diagnosis methods and thus enable medical staff to have
methods to help them respond quickly [75]. PCR-based tests to identify mutations in the katG
and rpoB genes that are associated with resistance to rifampicin and isoniazid, respectively,
may assist in the early identification of resistance to these drugs in mycobacteria [40]. The
WHO Stop TB Partnerships New Diagnosis Working Group and the Foundation for
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Innovative New Diagnosis (FIND) ranked tools for diagnosing active and drug-resistant TB in
three categories: (1) tools approved byWHO; (2) tools that are in the last phase of development
or evaluation and (3) tools that are in the early stages of development [76]. Tools approved by
WHO include LPAs for the diagnosis of MDR-TB, by GenoType® MTBDR plus, Hian
Lifescience, Nehren, Germany; INNO-LiPA Rif. TB, produced by Innogenetics, Ghent, Bel-
gium, an assay for rapid detection and speciation, whose manufacturer is Capilia TB-Neo,
TAUNUS, Numazu, Japan and the GeneXpert MTB/RIF system, produced by Cepheid, CA,
USA, a nucleic acid amplification test (NAAT) to screen for MTB-MDR. In the third group,
tools that are in the early stages of development include an assay based on the detection of
lipoarabinomannan, a breath analyzer, a loop-mediated isothermal amplification technology,
called TB-LAMP, produced by Eiken Chemical Co Ltd, Tokyo, Japan, and a phage-based
bioassay for the rapid diagnosis of MDR-TB [77]. Another very promising development is the
one belonging to the company Hain Life-science, Nehren, Germany. This technique is used to
screen resistance of MTB strains to second-line injectable drugs: amikacin, kanamycin and
capreomycin.
6.4.2. RT-PCR and line probe assay (LPA) for detecting MDR
The LPA is based on the principle of reverse hybridization, in which the 16S-23S spacer region
of the rRNA (ribosomal RNA) is amplified by PCR. The amplicons are hybridized with
oligonucleotide probes which are placed on nitrocellulose strips and are detected by a colori-
metric system (usually by the biotin/avidin system). The probe is biotinylated and the avidin is
covalently attached to a chromophore. There is currently a system for an LPA called Inno-LiPA
Mycobacteria, produced by Innogenetics, Belgium. Inno-LiPA Mycobacteria allows identifica-
tion of CMTB species, M. kansasii, M. xenopi, M. gordonae, M. avium complex, M. intracellulare,
M. scrofulaceum and M. chelonae-M abscessus complex species [78]. This system has demon-
strated an accuracy of 99.2%. INNO-LiPA Rif has also proven its usefulness in examining the
resistance/susceptibility of rifabutin in mycobacteria [79]. The LPAs allow obtaining results in
24 h, with a very high sensitivity (99%), as already mentioned above. This system is the only
one under development that will allow detection of MTB resistant to second-line drugs. The
limitation of LPAs is that in most resource-poor countries, the facilities required to avoid
contamination of amplicons, laboratory supplies and the equipment necessary to perform
amplification of genetic material by PCR are not available [80].
6.4.3. GeneXpert MTB/RIF
The method called GeneXpert MTB/RIF is based on real-time PCR and RT-PCR. The target is
the rpoB gene (encoding the beta subunit of RNA polymerase). This gene has in its sequence a
hot zone, which is very susceptible to mutations associated with resistance to rifampicin.
GeneXpert MTB/RIF is the fastest and safest system known until now, being able to produce
reliable results in less than 2 h. Therefore, GeneXpert MTB/RIF allows physicians making
accurate diagnoses and prescribing appropriate treatments, practically during the patients
visit to his office. GeneXpert MTB/RIF is fully automated. The system consists of an instru-
ment, a personal computer, a bar code reader and specialized preloaded software to interpret
the results. The system requires disposable GeneXpert cartridges that contain everything
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needed to perform nucleic acid amplification. As the cartridges are individual and watertight,
the possibility of cross-contamination and false results is eliminated. Concerning to usefulness
and availability of GeneXpert MTB/RIF, van Rie et al. [77] stated that is the first system that has
a true point of care [POC] tool in regions with limited resources. The automation and simplicity
of the GeneXpert MTB/RIF system allow non-mycobacteriology personnel to obtain reliable
results. According to WHO, GeneXpert MTB/RIF should be used as an initial test for the diag-
nosis of TB and in symptomatic patients having a high risk of be sick of MDR-TB. On the other
hand, one of the main limitations that GeneXpertMTB/RIF has is the fragility of the equipment,
especially in places where the power supply fails continuously. On the other hand, it is doubtful
whether the detection of resistance only to rifampicin is sufficient to guide a suitable treatment
in areas where there is a high incidence of polyresistance [81].
6.4.4. Proteomic molecular tools
Proteomics is one of the most recent technological advances, which will surely bring enormous
benefits in the diagnosis of fast and simple PTB. Significant progress has already been made in
this regard. The sources of MTB proteins are easier to obtain and analyze the serum or plasma
of patients with TB and to control the serum of healthy controls. Several focused papers on the
above-mentioned sense have already been published: (1) Deng et al. in 2011 [82]; (2) Liu et al.
in 2010 [83]; (3) Zhang et al. in 2012 [84] and (4) Liu et al. in 2011 [85]. However, this approach
is neither accessible nor suitable for microbiological laboratories. The reasons are as follows:
currently, the instruments required to perform a TB diagnosis are costly, very sophisticated
systems and software and a high degree of specialization are required, not only for the correct
handling of the equipment [mass spectrometers, generally associated with high-performance
liquid chromatography (HPLC) equipment]. In addition, once the main proteins are known,
other specialized databases must be identified and consulted to determine their function.
7. Immune molecular tools
Among molecular diagnosis methods, there are tools based on the detection of antibodies, for
instance, the Enzyme Linkage Immuno Assay (ELISA). That is, these techniques are based on
the use of serological tests [86]. The vast majority of patients with TB (90%) live in low- or
middle-income countries. In these countries, the diagnosis of TB is based on the identification
of AFB in unprocessed sputum samples and using conventional microscopes. Mycobacterial
culture methods partially alleviate the low sensitivity of the ZN microscopy method. Never-
theless, we have already discussed the limitations of this method and those of techniques
based on nucleic acids amplification.
7.1. Methods based on immunochromatography
Methods based on immunochromatography are suitable for use in low-income areas, because
these tests can be done without specialized equipment and with minimal training. The most
commonly used MTB detection tests are based on the detection of anti-MTB antibodies. One of
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the aspects to be considered in the evaluation of commercial methods or the design of new
methods based on the detection of anti-TB antibodies is that the profile of antigenic MTB
proteins that are recognized by the antibodies generated in the immune response of the host.
A possible limitation of these methods consists of that the set of antibodies used as biomarkers
varies according to the progression of TB [87]. Therefore, a reliable diagnostic tool based on an
adequate combination of antigens is still required. Currently, there are about 40 commercial
serological tests for rapid TB diagnosis. These systems use various antigen compositions to
detect patients with anti-MTB antibodies. However, there are insufficient data on its reliability
in patients with HIV/AIDS and uninfected persons.
7.2. Immunoprecipitation in cellulose acetate strips
A usual format for rapid TB diagnosis is to use cellulose acetate strips with one line for the
test to which MTB antigens have been prefixed and another line as a positive control having
predefined MTB antigens and human antibodies anti-MTB antigens. At the end of the strip,
a section is left where the patients blood or serum sample is placed, plus a suitable volume
of some saline buffer, and then, a conjugate of anti-human antibodies labeled with colloidal
gold or some chromophore is placed. A positive reaction is observed when the antibodies
from the patient and the conjugate migrate on the cellulose acetate strip, and immunopre-
cipitation occurs, and consequently, binding of the conjugate on the line with the preset
MTB antigens. On the other hand, the human chromophore/anti-antibody conjugate also
binds to the positive control line with the MTB antibody and the preselected human anti-
MTB anti-antibody. These tests take only a few minutes. Due to its usefulness and simplic-
ity, it is currently considered a high priority to rigorously evaluate these tests to take
advantage of them with safety and advantage as soon as possible. These tests are conducted
by the National TB Programs of the United States of America [86]. Even though immuno-
precipitation in cellulose acetate strips is considered as a promising tool, the WHO disap-
proves the use of such immunological methods for the diagnosis of TB, especially when it is
intended to replace the search for AFB with microscopy [88].
7.3. Enzyme Linkage Immuno Assay (ELISA)
ELISA serves as a presumptive test in cases of suspected TB. The ELISA plates are sensitized
with a complete soluble extract of M. bovis, strain BCG. The test serum is diluted, and after
addition of the immunoenzymatic conjugate and its substrate, the spectrophotometric reading
is made and it is determined whether it is positive or negative, according to the cutoff value
determined in 100 sera from apparent healthy subjects coming from an endemic area of TB.
The result is reported as positive or negative. Given the individual differences in response and
cross-reactions with antibodies induced by other mycobacteria, the negative result should be
interpreted with caution as it does not necessarily rule out TB [55]. Therefore, commercial
ELISA tests are considered to have limited sensitivity and inconsistent specificity for the
diagnosis of TB. Nevertheless, this method is the basis for interferon-gamma release assays
(IGRAs), which are useful to detect LTBI (see below), using interferon-γ detection, as we
discuss below.
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7.4. Interferon (INF)-γ
The basic utility of IFN-γ is the diagnosis of LTBI, although IFN-γ detection is also used
intensively for the diagnosis of active TB. Tests based on the measurement of IFN-γ release for
the diagnosis of TB are generically called IGRAs. The infection usually ends by infiltration into
the lung tissue of CD4+ T lymphocytes, which release IFN-γ. In turn, IFN-γ activates macro-
phages [89]. Identification of LTBI is a difficult issue. Therefore, the current diagnostic methods
are based on markers of infection. Because of this, the intradermal reaction described above has
long been used. Currently, kits are available to measure the release of IFN-γ as an immunodiag-
nosis alternative.
7.5. Interferon-gamma release assays (IGRAs)
IGRAs are designed to diagnose LTBI. These detect a cellular immune response to MTB. A
remarkable characteristic of IGRAs consists in that results produced by these methods are not
affected by the status of vaccination with BCG. Thus, in contrast with Mantoux method,
IGRAs are useful for evaluation of LTBI in BCG-vaccinated individuals, particularly in settings
where BCG vaccination was administered after infancy or multiple times. On the other hand,
the IGRAs limitations are as follows: (1) These are unable to distinguish between an LTBI and
an active-TB disease. (2) A positive IGRA result may not necessarily indicate an MTB infection,
because it can also be caused by a non-tuberculous mycobacteria infection. (3) A negative
IGRA does not rule out an active TB disease; many researchers have shown that up to a quarter
of patients with active TB have negative IGRA results.
The IGRAs mainly used in the world are base ELISPOT and Quanti-FERON Gold In-tube.
7.6. Enzyme-linked immunospot (ELISPOT) assay
One of the best-known IGRA is ELISPOT, produced by Abcam. This system is used to determine
the number of IFN-γ-producing T cells. ELISPOTemploys monoclonal or polyclonal antibodies
preferably monoclonal antibodies because of their greater specificity than polyclonal antibodies.
The antibodies are immobilized under aseptic conditions in the bottom of polyvinylidene fluoride
(PVDF) microplates. The microplates are blocked, usually with serum albumin, which does not
react with any antibody in the assay. Patients cells are deposited on the microtiter plates at
different densities in the presence of an antigen (in this case, the ESAT-6 MTB protein or the
CPF10 protein filtrate). Both targets are strongly specific for TH1 cells in anMTB infection and are
absent in BCG [90], whereas M. kansasii, M. szulgai, M.marinum, M. flavensens and M. gastric react
with MTB-ESAT-6 and MTB-CPF-10. Microplates are put in a wet chamber at 37C in an incuba-
tor with 5% CO2 atmosphere for the time indicated by each manufacturer [91]. The specificity in
HIV-infected individuals is 90%, while the specificity of the intradermal reaction is 57% [92].
7.7. Quanti-FERON Gold In-tubeTM (QFT-GIT)
QuantiFERON Gold In tube (QFT) was specifically designed to LTBI. QFT-GIT is produced by
QIAGEN. The QFT-GIT assay is an ELISA-based method. The test uses whole blood samples
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from LTBI-suspicious patients and peptides from three TB antigens (ESAT-6, CFP-10 and TB7.7)
in an in-tube format. The result is reported as quantification of IFN-γ in international units (IU)/
mL of blood. An individual is considered positive for LTBI if the concentration of IFN-gamma
concentration secreted by the responsive cells to TB antigens is higher than the test cut-off. These
estimations are made after subtracting the IFN-γ concentration found in the negative control
[93]. Several authors have reported that QFT-GIT has a sensitivity of 6493% with an average of
70% [94]. Diel et al. found an average of 88% sensitivity of QFT-GITwith a range of 8590% [95].
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